Categories: News

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights.

Conference Call and Webcast Information
Date: May 11, 2023
Time: 4:30 p.m. ET
Webcast Link: BioAtla First Quarter 2023 Earnings Conference Call
Dial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)
Conference ID: 13737960

The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.

About BioAtla, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with 716 patents (440 issued, 7 allowed, and 269 pending). Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first bispecific antibody, BA3182, targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.

Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945

External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

Staff

Recent Posts

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Conference Call and Webcast Scheduled for Tuesday August 12, 2025 at 4:30 PMWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus…

11 hours ago

GLOBO Language Solutions Honored as Silver Stevie® Award Winner for Technology Breakthrough of the Year − Artificial Intelligence

PHILADELPHIA, July 29, 2025 /PRNewswire/ -- GLOBO Language Solutions, the leading B2B provider of interpreting and…

11 hours ago

AI Just Got a Green Light from the White House–Here’s What That Means for Healthcare Stocks

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 29, 2025…

11 hours ago

Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report

ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the…

11 hours ago

Revolutionizing Patient Care Through Advanced Brain Monitoring and Generative AI

PHILADELPHIA, July 29, 2025 /PRNewswire/ -- In a bold step toward transforming neurocritical care, Moberg…

11 hours ago

PRC Enhances VoicesAI™ with Meta’s LLaMA to Deliver Predictive Comment Intelligence for Healthcare

Upgraded VoicesAI™ solution built with LLaMA—Meta's advanced open-source language model—delivers faster, smarter comment analysis and…

11 hours ago